Focusing on only 3 avenues in Nash, oncology and HIV. May I also remind you… HIV for which we already have a partner wether we feel we do or not we do have a partner there. This 3 avenue micro focused direction only diminishes our value as a possible platform drug. We could have a huge upside to show our indications we have excelled in and still need a phase 3 study completed by partner or a potential buy-out by another Pharma. Stopping those trials mentioned with the low cost of completing phase 1 or 2 trials for those indications we have and letting a partner have the indication for completing the phase 3 expensive trials and splitting the revenue or even holding ourselves the results of those trials for a buy-out is just smart in my opinion. The biggest future revenue and value is as a platform drug and that was my point. Bringing Leronlimab to a phase 2 for a few indications opens the door for the sale of a platform drug and the biggest by far return for our investment.